ENTRY       D01253                      Drug
NAME        Clobazam (JAN/USAN/INN);
            Mystan (TN);
            Onfi (TN)
PRODUCT     ONFI (Lundbeck Pharmaceuticals LLC)
            SYMPAZAN (Aquestive Therapeutics)
  GENERIC   CLOBAZAM (Accord Healthcare)
            CLOBAZAM (American Health Packaging)
            CLOBAZAM (Amneal Pharmaceuticals NY LLC)
            CLOBAZAM (Amneal Pharmaceuticals NY LLC)
            CLOBAZAM (Ascend Laboratories)
            CLOBAZAM (Ascend Laboratories)
            CLOBAZAM (Aurobindo Pharma Limited)
            CLOBAZAM (Bionpharma)
            CLOBAZAM (Bionpharma)
            CLOBAZAM (Breckenridge Pharmaceutical)
            CLOBAZAM (CELLTRION USA)
            CLOBAZAM (Camber Pharmaceuticals)
            CLOBAZAM (Camber Pharmaceuticals)
            CLOBAZAM (Chartwell RX)
            CLOBAZAM (Lupin Pharmaceuticals)
            CLOBAZAM (Lupin Pharmaceuticals)
            CLOBAZAM (MSN LABORATORIES PRIVATE LIMITED)
            CLOBAZAM (Micro Labs Limited)
            CLOBAZAM (NorthStar RxLLC)
            CLOBAZAM (NorthStar RxLLC)
            CLOBAZAM (Novadoz Pharmaceuticals LLC)
            CLOBAZAM (Sandoz)
            CLOBAZAM (Taro Pharmaceuticals U.S.A.)
            CLOBAZAM (Taro Pharmaceuticals U.S.A.)
            CLOBAZAM (Taro Pharmaceuticals U.S.A.)
            CLOBAZAM (Upsher-Smith Laboratories)
            CLOBAZAM (VistaPharm)
            CLOBAZAM (Zydus Lifesciences Limited)
            CLOBAZAM (Zydus Pharmaceuticals USA)
FORMULA     C16H13ClN2O2
EXACT_MASS  300.0666
MOL_WEIGHT  300.7396
CLASS       Neuropsychiatric agent
             DG01567  GABA-A receptor agonist
             DG01914  Anxiolytics, benzodiazepine derivatives
             DG03199  Antiepileptic agent
              DG02036  Benzodiazepine derivative, antiepileptic
            Metabolizing enzyme substrate
             DG01639  CYP2C19 substrate
             DG01633  CYP3A/CYP3A4 substrate
              DG02913  CYP3A4 substrate
REMARK      Therapeutic category: 1139
            ATC code: N05BA09
            Product: D01253<JP/US>
EFFICACY    Anticonvulsant, Minor tranquilizer
  DISEASE   Lennox-Gastaut syndrome [DS:H01813]
COMMENT     Benzodiazepine derivative
TARGET      GABR [HSA:2554 2555 2556 2557 2558 2559 2560 2561 2562 2563 2564 2565 2566 2567 2568 55879] [KO:K05175 K05181 K05184 K05185 K05186 K05189 K05192]
  PATHWAY   hsa04080(2554+2555+2556+2557+2558+2559+2560+2561+2562+2563+2564+2565+2566+2567+2568+55879)  Neuroactive ligand-receptor interaction
            hsa04727(2554+2555+2556+2557+2558+2559+2560+2561+2562+2563+2564+2565+2566+2567+2568+55879)  GABAergic synapse
METABOLISM  Enzyme: CYP3A4 [HSA:1576], CYP2C19 [HSA:1557]
INTERACTION  
STR_MAP     map07033  Anticonvulsants
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             N NERVOUS SYSTEM
              N05 PSYCHOLEPTICS
               N05B ANXIOLYTICS
                N05BA Benzodiazepine derivatives
                 N05BA09 Clobazam
                  D01253  Clobazam (JAN/USAN/INN) &lt;JP/US&gt;
            USP drug classification [BR:br08302]
             Anticonvulsants
              Gamma-aminobutyric Acid (GABA) Augmenting Agents
               Benzodiazepines
                Clobazam
                 D01253  Clobazam (JAN/USAN/INN)
            Therapeutic category of drugs in Japan [BR:br08301]
             1  Agents affecting nervous system and sensory organs
              11  Agents affecting central nervous system
               113  Antiepileptics
                1139  Others
                 D01253  Clobazam (JAN/USAN/INN)
            Drug groups [BR:br08330]
             Neuropsychiatric agent
              DG01567  GABA-A receptor agonist
               D01253  Clobazam
              DG01914  Anxiolytics, benzodiazepine derivatives
               D01253  Clobazam
              DG03199  Antiepileptic agent
               DG02036  Benzodiazepine derivative, antiepileptic
                D01253  Clobazam
             Metabolizing enzyme substrate
              DG01639  CYP2C19 substrate
               D01253  Clobazam
              DG01633  CYP3A/CYP3A4 substrate
               DG02913  CYP3A4 substrate
                D01253  Clobazam
            Drug classes [BR:br08332]
             Neuropsychiatric agent
              DG03199  Antiepileptic agent
               D01253  Clobazam
            Target-based classification of drugs [BR:br08310]
             Ion channels
              Ligand-gated ion channels
               GABA (ionotropic)
                GABR
                 D01253  Clobazam (JAN/USAN/INN) &lt;JP/US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D01253
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D01253
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D01253
            Drug metabolizing enzymes and transporters [br08309.html]
             Drug metabolizing enzymes
              D01253
            Pharmacogenomic biomarkers [br08341.html]
             Polymorphisms and mutations affecting drug response
              D01253
            Narcotics and psychotropics in Japan [br08308.html]
             Psychotropics by Cabinet order Article 3 (78 substances)
              D01253
DBLINKS     CAS: 22316-47-8
            PubChem: 7848316
            ChEBI: 31413
            LigandBox: D01253
            NIKKAJI: J11.411A
ATOM        21
            1   C5x C    20.8440  -16.6025
            2   C1x C    21.7290  -15.5177
            3   C5x C    21.4335  -14.1745
            4   N1y N    20.1974  -13.5636
            5   N1y N    19.4423  -16.6153
            6   C8y C    18.9128  -14.1417
            7   C8y C    18.5788  -15.4592
            8   C8x C    17.2356  -15.7546
            9   C8y C    16.2236  -14.8026
            10  C8x C    16.5605  -13.4152
            11  C8x C    17.9036  -13.1197
            12  X   Cl   14.8804  -15.0980
            13  O5x O    21.3522  -17.8843
            14  C8y C    18.7672  -17.7087
            15  C1a C    20.3245  -12.1676
            16  O5x O    22.5198  -13.3081
            17  C8x C    17.3603  -17.7403
            18  C8x C    16.6880  -18.9683
            19  C8x C    17.4154  -20.1645
            20  C8x C    18.8222  -20.1326
            21  C8x C    19.4945  -18.9046
BOND        23
            1     3   4 1
            2     1   5 1
            3     4   6 1
            4     2   3 1
            5     5   7 1
            6     1   2 1
            7     6   7 1
            8     7   8 2
            9     8   9 1
            10    9  10 2
            11   10  11 1
            12    6  11 2
            13    9  12 1
            14    1  13 2
            15    5  14 1
            16    4  15 1
            17    3  16 2
            18   14  17 2
            19   17  18 1
            20   18  19 2
            21   19  20 1
            22   20  21 2
            23   14  21 1
///
